Author

Cheol-Young Park

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Comparative effects of enavogliflozin versus dapagliflozin on adipokines in patients with type 2 diabetes mellitus: a pooled analysis of two randomized controlled trials

Although SGLT2 inhibitor–induced amelioration of adipokines is known to confer cardiometabolic benefits, it remains unclear whether individual SGLT2 inhibitors differ in their effects on adipokine regulation. In this study, we compared the effects of enavogliflozin and dapagliflozin on adipokine levels in patient...

Y. Lyu, Kyung-Soo Kim, H. Lee et al. · Cardiovascular Diabetology · 0 citations

Open access Jul 2026

Blood viscosity as a continuous marker of cardio-metabolic risk burden: a large-scale cross-sectional study of 38,574 adults

Aims Metabolic syndrome (MetS) is diagnosed using fixed thresholds that may not fully reflect the continuous accumulation of cardio-metabolic risk. We investigated whether whole blood viscosity (WBV) increases progressively with increasing MetS burden and explored the relative contribution of individual MetS components...

D. Lee, Byoungduck Han, Hongyup Ahn et al. · Frontiers in Endocrinology · 0 citations

Open access Jul 2026

Transcriptomic and metabolomic analyses reveal that lobeglitazone ameliorates hepatic steatosis in rats concurrent with regulation of mitochondrial pyruvate metabolism.

BACKGROUND AND PURPOSE Lobeglitazone is a thiazolidinedione and PPARγ agonist that improves metabolic parameters and hepatic steatosis, but its mechanisms are not fully understood. This study investigated the effects of lobeglitazone on hepatic transcriptomic and metabolic profiles in a rat model of obesity and Type 2...

Hyekyung Yang, S. Son, Youngmi Song et al. · British Journal of Pharmacol... · 0 citations